Share on LinkedInShare on LinkedIn

ARTICLE · 21 JUNE 2024

Orange Book Concerns Pick Up As Yet Another Issue For Pharmaceutical Manufacturers

Pharmaceutical manufacturers are increasingly finding themselves defending decisions to list in the U.S. Food and Drug Administration's (FDA) Orange Book patents that they assert are associated with their products.

United StatesIntellectual Property

Pharmaceutical manufacturers are increasingly finding themselves defending decisions to list in the U.S. Food and Drug Administration's (FDA) Orange Book patents that they assert are associated with their products. The Federal Trade Commission (FTC) issued a policy statement in September 2023 announcing an evaluation of whether improper Orange Book listings "may constitute an unfair method of competition in violation of Section 5 of the FTC Act." Two months later, the FTC sent letters to pharmaceutical manufacturers identifying more than 100 patents that the FTC believed had been improperly listed and added concerns with more than 300 patents in another round of letters sent in April 2024.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from